Pacira BioSciences Successfully Transitions PCRX-201 To A Scalable Commercial Manufacturing Process In The U.S.; Topline Data From Part A Of Phase 2 ASCEND Study Remains On Track For End Of 2026
Pacira Biosciences Inc PCRX
$26.41
▼ -2.08%
($-0.56)
📅 Earnings This Week
Open
$26.86
Prev Close
$26.97
Day Range
$25.97 – $27.03
52W Range
$18.80 – $27.64
Market Cap
$1.04B
P/E (TTM)
202.19
Beta
0.25
EPS (TTM)
$0.13
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2011-02-03 |
| Shares Out. | 39,350,000 |
| Website | pacira.com/ ↗ |
| Phone | 13026587581 |
| Employees | 829 |
| Revenue | $177.4M |
| Gross Profit | $141.0M |
| Net Income | $2.9M |
| Free Cash Flow | $132.7M |
| Total Assets | $1.21B |
| Total Liabilities | $554.6M |
| Equity | $653.9M |
About Pacira Biosciences Inc
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Pacira Biosciences Inc is a publicly traded company under the ticker symbol PCRX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-07-01)